Single-chain Fv Antibodies for Targeting Neurodegenerative Diseases

Author(s): Kin Yen Chia, Khuen Yen Ng, Rhun Yian Koh, Soi Moi Chye*

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 17 , Issue 9 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background & Objective: Protein misfolding and aggregation have been considered the common pathological hallmarks for a number of neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD). These abnormal proteins aggregates damage mitochondria and induce oxidative stress, resulting in neuronal cell death. Prolonged neuronal damage activates microglia and astrocytes, development of inflammation reaction and further promotes neurodegeneration. Thus, elimination of abnormal protein aggregates without eliciting any adverse effects are the main treatment strategies. To overcome this, recent studies have deployed single- chain fragment variable antibodies (scFvs) to target the pathological protein aggregates, such as amyloid-beta (Aβ) peptides, α-synuclein (α-syn) and Huntingtin (Htt). To date scFv has been effective at inhibiting abnormal protein aggregates formation in both in vitro and in vivo model system of AD, PD and HD.

Conclusion: Currently active research is still ongoing to improve the scFv gene delivery technology, to further enhance brain penetration, intracellular stability, solubility and efficacy of scFv intrabody.

Keywords: Inflammation reaction, neurodegenerative disease, oxidative stress, single-chain Fv antibodies, pathological, Alzheimer's disease.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 01 November, 2018
Page: [671 - 679]
Pages: 9
DOI: 10.2174/1871527317666180315161626
Price: $65

Article Metrics

PDF: 43